Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.55 |
| ▸ | RELA | Q04206 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | CASP3 | P42574 | 1/20 | 0.55 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.55 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.55 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | MAOB | P27338 | 4/20 | 0.51 |
| ▸ | MAOA | P21397 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31560392 | 1.00 | ALOX5 (0.62) | ALOX5SMN1; SMN2NPC1RAB9AMAPT | |
| Trifluoroacetic Acid SCHEMBL16669663 | 0.89 | ALOX5 (0.52) | ALOX5SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL4539281 | 0.86 | ALOX5 (0.54) | ALOX5SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL16397645 | 0.84 | ALOX5 (0.64) | ALOX5SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL212724 | 0.84 | ALOX5 (0.64) | ALOX5SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL919529 | 0.83 | ALOX5 (0.48) | ALOX5SMN1; SMN2NPC1RAB9AMAPT | |
| Hydrochloric Acid SCHEMBL23532714 | 0.82 | ALOX5 (0.62) | ALOX5SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL9058393 | 0.82 | ALOX5 (0.67) | ALOX5SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL2154729 | 0.82 | ALOX5 (0.62) | ALOX5SMN1; SMN2NPC1RAB9AMAPT | |
| Hydrochloric Acid SCHEMBL5770308 | 0.82 | ALOX5 (0.62) | ALOX5SMN1; SMN2NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024222918-A1 | BENZO SIX-MEMBERED HETEROCYCLIC GSPT1 PROTEIN DEGRADATION AGENT AND USE THEREOF | 中国药科大学 | 2024-10-31 | — | — | WO | disclosed |
| EP-4267553-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-4180423-A1 | NOVEL TNF ACTIVITY INHIBITOR COMPOUND, AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ILAb Co., Ltd. (KR) | 2023-05-17 | — | — | EP | disclosed |
| WO-2023070780-A1 | MONOAMINE OXIDASE B INHIBITOR HAVING POTENTIAL IRON CHELATING ACTIVITY AND USE THEREOF | 浙江工业大学 | 2023-05-04 | — | — | WO | disclosed |
| US-20230094176-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENT AB (SE) | 2023-03-30 | — | — | US | disclosed |
| CN-111346088-B | Application of pyranochromene-3-formamide derivative Z20 in preparation of medicines for preventing and treating organ injury caused by sepsis | 南方医科大学 | 2022-07-01 | — | — | CN | disclosed |
| WO-2022140520-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| CN-113166123-A | Novel insect repellent compounds | 拜耳动物保健有限责任公司 | 2021-07-23 | — | — | CN | disclosed |
| EP-3837262-A1 | N-CYANO-7-AZANORBORNANE DERIVATIVES AND USES THEREOF | Amgen Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| CN-112654628-A | Selenophenochromic hydroxamic acid, preparation and application as angiogenesis inhibitor | 拉脱维亚有机合成学院 | 2021-04-13 | — | — | CN | disclosed |
| WO-2012120262-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | LARSSON PIA (SE) | 2012-09-13 | — | — | WO | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20110263642-A1 | METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS | FIBROGEN, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| EP-2341904-A1 | METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS | Fibrogen, Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| US-20100298580-A1 | Process for the Preparation of 2H-Chromene-3-Carbamate Derivatives | BIAL - PORTELA & CA, S.A. (PT) | 2010-11-25 | — | — | US | disclosed |
| WO-2010024908-A1 | METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS | FIBROGEN, INC. (US) | 2010-03-04 | — | — | WO | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | GLAXO GROUP LIMITED (GB) | 2007-03-15 | — | — | US | disclosed |
| US-6414013-B1 | KINASE INHIBITORS; ANTICANCER AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2002-07-02 | — | — | US | disclosed |
| WO-2001072735-A2 | BENZOPYRANES USEFUL AS TNF ALPHA INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298580-A1 | Process for the Preparation of 2H-Chromene-3-Carbamate Derivatives | CYP8B1, CYP4B1, CYP3A4 | ALOX5 3347/4885SMN1; SMN2 2508/4885NPC1 3028/4885 |
| US-20110263642-A1 | METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS | PMP22, MAG, NEFM | ALOX5 239/4885SMN1; SMN2 97/4885NPC1 1125/4885 |
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | HRH3, HRH4, HRH1 | ALOX5 2396/4885SMN1; SMN2 2487/4885NPC1 2009/4885 |
| US-20230094176-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC2, HDAC1 | ALOX5 1060/4885SMN1; SMN2 3053/4885NPC1 2295/4885 |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | ALOX5 3821/4885SMN1; SMN2 3423/4885NPC1 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.